These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

134 related articles for article (PubMed ID: 38795097)

  • 1. Inhaled Oral Flecainide for Rapid Cardioversion of Atrial Fibrillation.
    Kiani S
    JACC Clin Electrophysiol; 2024 Jun; 10(6):1034-1036. PubMed ID: 38795097
    [No Abstract]   [Full Text] [Related]  

  • 2. Favorable effects of flecainide in transvenous internal cardioversion of atrial fibrillation.
    Boriani G; Biffi M; Capucci A; Bronzetti G; Ayers GM; Zannoli R; Branzi A; Magnani B
    J Am Coll Cardiol; 1999 Feb; 33(2):333-41. PubMed ID: 9973012
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Direct-current cardioversion of atrial tachyarrhythmias under oral flecainide therapy.
    Leclercq JF; Bizot J; Attuel P; Coumel P
    Am J Cardiol; 1997 Sep; 80(5):645-8. PubMed ID: 9295002
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Importance of left atrial diameter and atrial fibrillatory frequency for conversion of persistent atrial fibrillation with oral flecainide.
    Bollmann A; Binias KH; Toepffer I; Molling J; Geller C; Klein HU
    Am J Cardiol; 2002 Nov; 90(9):1011-4. PubMed ID: 12398975
    [No Abstract]   [Full Text] [Related]  

  • 5. Effects of pretreatment with intravenous flecainide on efficacy of external cardioversion of persistent atrial fibrillation.
    Climent VE; Marin F; Mainar L; Gomez-Aldaravi R; Martinez JG; Chorro FJ; Roman P; Sogorb F
    Pacing Clin Electrophysiol; 2004 Mar; 27(3):368-72. PubMed ID: 15009866
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Orally Inhaled Flecainide for Conversion of Atrial Fibrillation to Sinus Rhythm: INSTANT Phase 2 Trial.
    Ruskin JN; Camm AJ; Dufton C; Woite-Silva AC; Tuininga Y; Badings E; De Jong JSSG; Oosterhof T; Aksoy I; Kuijper AFM; Van Gelder IC; van Dijk V; Nuyens D; Schellings D; Lee MY; Kowey PR; Crijns HJGM; Maupas J; Belardinelli L;
    JACC Clin Electrophysiol; 2024 Jun; 10(6):1021-1033. PubMed ID: 38613545
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Short-term versus long-term antiarrhythmic drug treatment after cardioversion of atrial fibrillation (Flec-SL): a prospective, randomised, open-label, blinded endpoint assessment trial.
    Kirchhof P; Andresen D; Bosch R; Borggrefe M; Meinertz T; Parade U; Ravens U; Samol A; Steinbeck G; Treszl A; Wegscheider K; Breithardt G
    Lancet; 2012 Jul; 380(9838):238-46. PubMed ID: 22713626
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Idiopathic atrial fibrillation of recent onset and atrial stunning: the echocardiographic evidence after pharmacological cardioversion].
    Ciolli A; De Sisti A; Montenero AS; Sanna T; Lo Sardo G; Palamara A
    Cardiologia; 1998 Oct; 43(10):1077-82. PubMed ID: 9922572
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Oral loading single dose flecainide for pharmacological cardioversion of recent-onset atrial fibrillation.
    Khan IA
    Int J Cardiol; 2003 Feb; 87(2-3):121-8. PubMed ID: 12559528
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Flecainide for cardioversion in patients at elevated cardiovascular risk and persistent atrial fibrillation: a prospective observational study.
    Er F; Aslan O; Caglayan E; Gassanov N; Nia AM; Erdmann E; Rosenkranz S
    Clin Res Cardiol; 2010 Jun; 99(6):369-73. PubMed ID: 20180126
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Tissue velocity imaging of the left atrium predicts response to flecainide in patients with acute atrial fibrillation.
    Limantoro I; De Vos CB; Delhaas T; Marcos E; Blaauw Y; Weijs B; Tieleman RG; Pisters R; Schotten U; Van Gelder IC; Crijns HJ
    Heart Rhythm; 2014 Mar; 11(3):478-84. PubMed ID: 24321238
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effectiveness and safety of vernakalant vs flecainide for cardioversion of atrial fibrillation in the emergency department: the VERITA study.
    Dominijanni G; Caballero-Bermejo AF; Martín Jiménez ML; Calpe Delgado P; Rodríguez-Miranda B; Ruiz-Antorán B
    Emergencias; 2024 Jun; 36(3):239-240. PubMed ID: 38819000
    [No Abstract]   [Full Text] [Related]  

  • 13. Treatment of recent onset atrial fibrillation with intravenous sotalol and/or flecainide.
    Peters FP; Braat SH; Heymeriks J; Wellens HJ
    Neth J Med; 1998 Sep; 53(3):93-6. PubMed ID: 9803139
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Electrophysiological effects of flecainide and sotalol in the human atrium during persistent atrial fibrillation.
    Kirchhof P; Engelen M; Franz MR; Ribbing M; Wasmer K; Breithardt G; Haverkamp W; Eckardt L
    Basic Res Cardiol; 2005 Mar; 100(2):112-21. PubMed ID: 15696400
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cardioversion threshold, IRAF and beyond.
    Merckx KL; Tieleman RG; Crijns HJ
    Eur Heart J; 2004 Jun; 25(11):997. PubMed ID: 15172478
    [No Abstract]   [Full Text] [Related]  

  • 16. Prospective comparison of flecainide versus sotalol for immediate cardioversion of atrial fibrillation.
    Reisinger J; Gatterer E; Heinze G; Wiesinger K; Zeindlhofer E; Gattermeier M; Poelzl G; Kratzer H; Ebner A; Hohenwallner W; Lenz K; Slany J; Kuhn P
    Am J Cardiol; 1998 Jun; 81(12):1450-4. PubMed ID: 9645896
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Open-Label, Multicenter Study of Flecainide Acetate Oral Inhalation Solution for Acute Conversion of Recent-Onset, Symptomatic Atrial Fibrillation to Sinus Rhythm.
    Crijns HJGM; Elvan A; Al-Windy N; Tuininga YS; Badings E; Aksoy I; Van Gelder IC; Madhavapeddi P; Camm AJ; Kowey PR; Ruskin JN; Belardinelli L;
    Circ Arrhythm Electrophysiol; 2022 Mar; 15(3):e010204. PubMed ID: 35196871
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Randomised double blind trial of oral versus intravenous flecainide for the cardioversion of acute atrial fibrillation.
    Alp NJ; Bell JA; Shahi M
    Heart; 2000 Jul; 84(1):37-40. PubMed ID: 10862585
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Systematic review and meta-analysis of the efficacy of cardioversion by vernakalant and comparators in patients with atrial fibrillation.
    Bash LD; Buono JL; Davies GM; Martin A; Fahrbach K; Phatak H; Avetisyan R; Mwamburi M
    Cardiovasc Drugs Ther; 2012 Apr; 26(2):167-79. PubMed ID: 22418856
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Intravenous vernakalant in comparison with intravenous flecainide in the cardioversion of recent-onset atrial fibrillation.
    Pohjantähti-Maaroos H; Hyppölä H; Lekkala M; Sinisalo E; Heikkola A; Hartikainen J
    Eur Heart J Acute Cardiovasc Care; 2019 Mar; 8(2):114-120. PubMed ID: 28849946
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.